Go to Home


Meet the partners

James Chubb, Ph.D.

James Chubb, Ph.D. is broadly experienced in operational management, strategy and financing of biopharmaceutical companies, as well as possessing extensive pharmaceutical product development experience.

As a senior executive at Glaxo with more than 12 years of experience, Dr. Chubb was responsible for directing the filing of more than 15 NDA's and ANDs for anti-bacterial and anti-fungal drugs, beta agonist bronchodilators and inhaled steroids for asthma, topical steroids for dermatological indications and serotonin antagonists for cancer induced nausea and vomiting. As President and Chief Executive of Triplex Pharmaceuticals and its successor, Aronex Pharmaceuticals, for 8 years, Dr Chubb raised over $65 million in financing, and established several corporate partnerships. He built a strong management team and over saw advancement of three cancer drugs and an anti fungal into clinical trials. Dr. Chubb was subsequently founder and principal of ProPharma International Partners, Inc, a consulting and advisory service company to biotechnology companies, with locations in the San Francisco Bay area and London, UK.

Dr. Chubb received his Ph.D. in Pharmacology from the University of Arizona College of Medicine and completed a cardiovascular research fellowship at Michigan State University.

Peter Cozens, Ph.D.

Peter Cozens has worked for more than 27 years in the pharmaceutical industry. He is a scientifically-qualified commercial development professional with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry. Experienced in all facets of identifying, negotiating and managing third party agreements in all major territories to facilitate strategic business expansion. Additional responsibility in managing Patents and Trademark functions, including overseeing multinational patent litigation, many cases of which gave rise to seminal patent law, has provided valuable experience in contractual and intellectual property law. Experience also includes management of an export function responsible for sales outside Europe and the US and responsibility for strategic marketing/business information. A molecular geneticist by training on completion of his PhD, in 1978 Peter joined Ciba-Geigy (now Novartis) in Basel, Switzerland as a research scientist. In 1981 he moved to Wellcome Biotechnology Ltd. to work as a senior scientist in Molecular Biology and became leader of Wellcome’s cytokine programme. From 1987 to 1991, whilst still at Wellcome, he worked with Group Patents and Agreements on both patent litigation and licensing activities.

In 1991 he joined Medeva PLC where he became Executive Vice President, Business Development and Intellectual Property and a member of Medeva’s Executive Management Committee. Peter’s major achievement during this period was the building of Medeva’s development pipeline. He was responsible for a series of in-licensing and out-licensing deals and acquisitions including partnerships with Janssen, Connetics Corporation, Targeted Genetics, Peptide Therapeutics, SmithKline Beecham, ML Labs, Aviron, Mayo Medical Ventures, Eurand and Chiroscience. Peter also piloted the Biogen v. Medeva patent case through several courts culminating in the landmark House of Lords decision on the scope of patent claims. He is Chairman of the Intellectual Property Advisory Committee of the UK BioIndustry Association and a Non-Executive Director of Eden BioPharma Limited.

Geoffrey Kitson, M.D.

Geoff has gained a broad-based international perspective on drug development, from phase I to phase IV, experience of pre-clinical work, and regulatory requirements, since joining the pharmaceutical industry in 1988. He has been involved in the preparation of INDs, CTXs/CTAs, MAAs and other regulatory documents. He has experience in the development of individual clinical studies, clinical trial programmes, running multinational clinical trials and developing clinical strategies. In the last few years he has taken 5 products through to first in man studies, and progressed products through to Phase II/III.

Geoff obtained his medical degree from the University of Nottingham and initially trained and worked in anaesthesiology and intensive care before joining the pharmaceutical industry with Syntex Pharmaceuticals Limited. In various roles at Syntex he worked in a number of therapeutic areas, primarily pain, but also including female health care and cardiology. He was instrumental in the approval of ketorolac in the UK and maintaining the approval throughout Europe. Prior to the take over of Syntex by Roche Geoff worked in the USA, overseeing all ketorolac clinical trials worldwide, including planning the 16,000 patients "SAMM" study undertaken in Europe at the request of he CPMP. Geoff then joined Yamanouchi Pharma as the UK Medical Director. Wishing to move to earlier clinical development he moved to Head of Clinical Development at Chiroscience and then to Director of Exploratory Development World-wide at Medeva.

Before joining ProPharma, Geoff served as a consultant to start up companies offering services in clinical trial development and possible clinical strategies and identifying therapeutics areas for products.

Paulo Rangel, MBA.

Paulo S. Rangel concentrates on working with biopharmaceutical and medical device companies on worldwide in- and out-licensing.

Mr. Rangel was a Founder, President & CEO of Lasercure Sciences, a medical device start-up focused on the use of lasers to treat diabetic foot ulcers and pain. Mr. Rangel completed the financing, a diabetic foot ulcer clinical study, two collaborations, and filed two patents (an inventor on both).  Before Lasercure, Mr. Rangel was a Founder and Chief Business Officer of 5i Sciences, a start-up focused on a new approach to treat sleep apnea.  As CBO, Mr. Rangel is responsible for the company’s intellectual property, finance and general strategy. 

Mr. Rangel was the head of Business Development at Arizeke Pharmaceuticals, a respiratory company, from December 2000 to August 2006.  While at Arizeke, Mr. Rangel completed license agreements, renegotiated existing agreements and was responsible for intellectual property, business planning, evaluation of new product opportunities and certain financial projects.  Prior to joining Arizeke, Mr. Rangel was Director of Business Development at Universal Preservation Technologies from September 1998 to December 2000.  Between 1990 and 1998, Mr. Rangel was in the finance department at Hybritech, Inc. and was also involved in the start-up of four biotechnology companies, two of which were successfully acquired by large companies.  Earlier, he was at Amgen Inc., focused on the process scale-up of erythropoietin.

Mr. Rangel received a B.A. in chemistry/biochemistry from the University of California at San Diego and an M.B.A. from Duke University.

Andy Baxter, Ph.D.

In a career spanning 25 years, Andy has held senior technical and management positions in major pharmaceutical companies, emerging biotech companies and, most recently, small virtual pharmaceutical companies. Companies include, Pfizer, Chiroscience-Celltech, Arakis and Serentis. Andy has in-depth experience of the drug discovery process leading programmes through lead generation, lead optimisation and candidate selection. Andy has a broad understanding of most therapeutic areas and has experience of many therapeutic targets. He is an inventor or co-inventor of over 60 patent applications. In addition, Andy has many years of experience managing development programmes and has a broad technical and quality understanding of pre-clinical, chemistry, manufacture and controls (CMC), regulatory and early clinical operations. He has developed products as solid dose forms (including modified release), parental, topical, inhaled, intra-nasal, sub-lingual and transdermal patches. Andy has been successfully involved in both in-licensing and out-licensing projects and has managed collaborations between biotech and major pharmaceutical companies on a multidisciplinary level.

Phil Nichols, M.D.

Phil Nichols is a physician by training (BMedSci, MBBS Newcastle 1991) and continues to practice one day per week as a Consultant Neurologist for the NHS (Royal Victoria Infirmary, Newcastle). He is a Fellow of the Royal College of Physicians (UK) and a member of the Association of British Neurologists. He has a postgraduate PhD qualification in Medicine (MRC Clinical Research Fellowship, DPhil, St. John’s College, Oxford) and won a Department of Health Clinician Scientist Award studying the mechanisms underlying chronic multiple sclerosis from 2002-’07. He continues to hold a part time academic Senior Lecturer position at Newcastle University. From 2005-’09 he held the position of Chief Medical Officer and Head of Clinical Development at Cambridge Laboratories (Ireland) Ltd, a UK & Ireland based entrepreneurial pharmaceutical company specializing in CNS and oncology products. He had overall responsibility for pre-clinical and clinical phases of drug development and was a member of the value realization team negotiating the recent sale of a major pharmaceutical asset (Tetrabenazine, Xenazine/Nitoman) for $230 million to BIOVAIL in 2009.

Jill Rasmussen, M.D.

Jill obtained her medical degree from Manchester and has held senior positions in the Pharma Industry in Europe and the US including positions with the Wellcome Foundation, Lundbeck Ltd, UK, SmithKline Beecham, Duphar BV (The Netherlands, now Solvay Pharmaceuticals) & Kali-Duphar Inc (U.S.A., now also part of Solvay). During her time in the industry Jill has worked in the following therapeutic areas, affective disorders (depression, dysthymia); anxiety and phobic states (generalised anxiety disorder, panic disorder with and without agoraphobia, social anxiety disorder), Obsessive Compulsive Disorder; psychoses (schizophrenia, bipolar disorder); sleep and circadian rhythm disorders; dementia (Alzheimer’s, Lewy Body, vascular); Neurological disorders (Parkinson's disease, epilepsy, migraine, pain). Jill has also gained experience as a Senior Medical Assessor with the UK regulatory agency the MHRA (formerly the MCA).

In 1999 in recognition of her services to CNS research, she was made a Fellow of the Faculty of Pharmaceutical Medicine. From 2002 to 2004, she was the Director of the UK National Neuroscience Institute.

In addition to her work in ProPharma, Jill maintains a part-time clinical commitment as a community specialist in psychiatry and neurology.

She is a member of major international psychopharmacology and neurology organisations and attends relevant conferences to remain at the cutting edge of both the therapeutic areas and developments in worldwide clinical trial methodology and regulatory strategy.

From 2002 to 2004, Jill was a member of the British Association of Psychopharmacology Council. Since 2004 she has been elected to the Board of the International Psychogeriatric Association.

Paul Cossum, Ph.D.

Paul Cossum has more than 20 years of experience in the biotechnology industry. He began his career as a scientist in the Pharmacological Sciences Department at Genentech Inc. There he worked on the metabolism and toxicity of recombinant human proteins, as well as peptides, in support of new therapeutics entering clinical trials. Over the next two decades he assumed increasingly broader roles and responsibilities in drug development at Isis Pharmaceuticals, Aronex Pharamceuticals and Newbiotics Pharmaceuticals. Most recently Paul was President and CEO of Proacta Inc., an early stage oncology focused discovery and development company. Much of his experience has focused on the interface between discovery and development, although he has also been responsible for preclinical sections of New Drug Applications (NDAs). Therapeutic areas of knowledge include inflammation, oncology, anti-infectives, cardiovascular, neurology and endocrinology. He has experience with small molecules, recombinant proteins, peptides, oligonucleotides, monoclonal antibodies and gene therapy. Paul holds Bachelor, Masters and PhD degrees from the University of Tasmania, Australia.

Yasuhiro Takahashi

Yasuhiro Takahashi has more than 25 years experience in pharmaceutical and health-care companies including: management of Japanese business operations of U.S. bio-venture firm, business development and commercialization of biopharmaceuticals & clinical diagnostic tests, clinical development of biopharmaceuticals in Japan, licensing of biopharmaceuticals and clinical diagnostic assays to Japanese firms. Prior to founding Biolink International, Inc., served as President, Nippon Centocor KK, Deputy General Manager, Abbott Japan. Member of Japan Bio-Industry Association, Licensing Executive Society, Japanese Bio-Venture Development Association, Organizing Committee Member of Kanto Area Genome Network, Officer of Pharma Delegates, Council Member of the America-Japan Society.

Mitsutoshi Hamano, Ph.D.

Mitsutoshi. Hamano held management positions in the Central Research Institute, and served as Director of Plant Cell Fusion and Biotechnology, Director of Business Development of Kikkoman, Director of Allergen Free Technology Institute, Director of Kikkoman Food Culture Institute and Council Member of Japan Food Science and Engineering Society. Received Ph.D. in Applied Microbiology, University of Tokyo. Graduated from Agricultural Chemistry, Nihon University

Hirouki Terayama, Ph.D.

More than 35 years of experience in pharmaceutical industry and held numerous technical and management positions including General Manager,Physical & Chemical Research Laboratory and Pharmaceutical Formulation Laboratory, Vice Director, Business Development Department, SmithKline Beecham Pharmaceutical Co., Ltd., General Manager, Pharmaceutical Development Division, Vexon Co., Ltd., and President Collect Medica Co, Ltd. Holds B.Sc. in Pharmacy, Tokyo Science University, and Ph.D. in Biosciences, Saitama University.

+1 510 681 4445